Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/30/12  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mark McKeage

Wrong Dr. Mark McKeage?

Co-Director, Associate Professor

Local Address: New Zealand
Auckland Cancer Centre
 
Background

Employment History

  • Key Investigator
    University of Auckland , New Zealand
  • Member, AS1404 Lung Cancer Study
    University of Auckland , New Zealand
  • Associate Professor In Clinical Pharmacology
    University of Auckland , New Zealand
  • Associate Professor In Clinical Pharmacology
    University of Auckland
  • Auckland Theatre Company

Education

  • Ph.D.
53 Total References
Web References
For the first time we will ...
www.mauricewilkinscentre.org, 30 Aug 2012 [cached]
For the first time we will be screening patients for the genetic mutation that causes drug resistance and then enrolling them in a trial of a New Zealand drug designed to target that mutation," says ACSRC Co-Director, Associate Professor Mark McKeage, the Clinical Oncologist leading the Auckland City Hospital trial, referring to the phase II part of the phase I/II trial.
...
Drs Jeff Smaill and Adam Patterson, Professor Bill Denny and Associate Professor Mark McKeage are all Maurice Wilkins Centre investigators.
Antisoma plc - Positive survival data from ASA404 trial presented at World Conference on Lung Cancer
www.antisoma.com, 5 Sept 2007 [cached]
Dr Mark McKeage of the University of Auckland, New Zealand, an investigator in both ASA404 lung cancer trials and the presenter of the new data in Korea, said: "This is a second set of positive data on ASA404 in lung cancer.
Antisoma PLC Second Lung Cancer Trial Adds To Positive Data On AS1404
www.keatshealthcare.co.uk, 3 Sept 2007 [cached]
Dr Mark McKeage of the University of Auckland, New Zealand, a key investigator in both AS1404 lung cancer studies, said: "The high response rate and favourable tolerability profile in this study support earlier data suggesting that AS1404 has real potential as a novel therapy for lung cancer."
Antisoma plc - Antisoma reports survival advantage for AS1404 in lung cancer and regains product rights
www.antisoma.com, 4 June 2006 [cached]
Dr Mark McKeage of the University of Auckland, New Zealand, one of the Principal Investigators in the AS1404 lung cancer study and the presenter of the findings at ASCO, said: "These are undoubtedly some of the most interesting data to emerge in lung cancer in recent years, and I look forward to seeing the drug proceed rapidly into phase III trials."
When added to traditional chemotherapy, ...
www.elainejesmer.com, 1 Mar 2010 [cached]
When added to traditional chemotherapy, the new drug, called vadimezan and also known as ASA404 or DMXAA, extended survival time, says Mark McKeage, PhD, an associate professor in clinical pharmacology at the University of Auckland, New Zealand, who presented the findings at the American Association for Cancer Research -- International Association for the Study of Lung Cancer meeting.
"Overall survival was improved numerically from a median of 8.8 to 14 months (half lived longer, half less). The safety profile is favorable."
In the phase II study, McKeage and his colleagues evaluated 108 patients who had advanced (stage IIIb or IV) NON-SMALL-CELL LUNG CANCER, the most common type of lung cancer. They assessed 104 of them for the safety evaluation and 100 to compare survival differences. Non-small-cell lung cancer is further divided into squamous cell carcinoma (cancer that originates from squamous cells, which are cells that line the airways) and non-squamous cell carcinoma, which includes other cell types. Patients received either standard chemotherapy or chemo plus the new drug. Two different doses of the new drug were tried, McKeage says.
Lung Cancer Drug: Study Results
Giving patients the drug in addition to chemo didn't increase the toxicity of the chemo, McKeage found, and survival was greater with the combined approach at either dose. When he looked at those with squamous cancers, survival was 10.2 months in those who got the drug plus the chemo, compared with 5.5 months in those who received chemo alone. For patients with non-squamous cancers, survival was 14.9 months with the combination therapy but 11 months on chemo alone.
"The range in survival is from a few weeks up to over a year, 18 months," he says. "One of these people is still alive, disease free, over four years after treatment. This patient had a fantastic response and then went [on] and had surgery [for the cancer]."
The most commonly reported side effects were blood and lymphatic disorders, reported by about 18%, but no serious adverse events were reported with lung hemorrhage or bleeding, a side effect that has accompanied other lung cancer drug therapy, McKeage says. The improvement is encouraging and warrants further investigation by proceeding to the phase III trial.
McKeage was the principal investigator for the study, which was funded by Antisoma, who later licensed the drug to Novartis Pharmaceuticals Corp. McKeage has consulted for both companies and received research funds from both.
Vadimezan works in a different way than another cancer drug that focuses on blood vessels, Avastin, McKeage says. They compare favorably, but vadimezan has fewer side effects.
Recruitment for the phase III study is complete, he says. He predicts the new drug may be on the market by 2012 or so.
"One of the important points of this analysis is that it shows the efficacy and safety profile [of the drug] was similar in squamous and non-squamous patients," McKeage says.
Other People with the name "McKeage":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304